Ad
related to: factor viii manufacturers- Family Planning Info
Bleeding disorders and pregnancy.
Steps to take before pregnancy.
- Education Specialists
Find a disease education
specialist near you.
- Patient Resources
Find helpful resources and videos
for rare bleeding disorders.
- Pain Management Info
Managing pain is possible.
Understanding pain & management.
- Family Planning Info
Search results
Results from the WOW.Com Content Network
Coagulation factor VIII (Factor VIII, FVIII, also known as anti-hemophilic factor (AHF)) is an essential blood clotting protein. In humans, it is encoded by F8 gene . [ 5 ] [ 6 ] Defects in this gene result in hemophilia A , an X-linked bleeding disorder .
A purified factor VIII concentrate is made from human blood plasma. [14] A recombinant version is also available. [13] People may develop antibodies to factor VIII such that this medication becomes less effective. [15] Factor VIII was first identified in the 1940s and became available as a medication in the 1960s.
Hemophilia A causes a deficiency in Factor VIII, a protein required for blood clotting. Factor VIII injections are a common treatment to prevent or stop bleeding in people with hemophilia A. [1] Contamination of these and other products caused large numbers of hemophiliacs to become infected with HIV and hepatitis C.
Octapharma was founded in 1983 by Wolfgang Marguerre, a German businessman who had previously worked in the pharmaceutical industry. The name Octapharma is derived from the Greek word for eight, referring to Factor VIII, the blood clotting protein deficient in patients with haemophilia A.
This partnership was extended the following year to also include the development of a long-lasting recombinant factor VIII Fc fusion protein candidate, rFVIIIFc, for the treatment of hemophilia A. In 2008, an agreement with Amgen regarding the acquisition of the products Kepivance and Stemgen as well as a global license for Kineret was signed
Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. [5] [6] [7] Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc). [5]
Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.
It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding. [6] The human coagulation factor VIII in moroctocog alfa is not extracted from human blood but is produced by a method known as 'recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to ...
Ad
related to: factor viii manufacturers